Brands
Learn more about what Meitheal Pharmaceuticals is doing to deliver on its vision of Healthcare Solutions within reach.
Watch Video- Brands
- Pipeline
Our Brands
Meitheal Pharmaceuticals is committed to helping solve unmet needs by being focused within the biopharma industry on products that make a difference. Our dedication to this goal is demonstrated through our development pipeline and initiatives including recent acquisitions of YUSIMRY® and CONTEPO™ (pending FDA approval) that will have a positive impact on patient care.
XTMAB-16
This chimeric human-murine anti-tumor necrosis factor α (TNFα) is being developed as a novel biologic product specifically for the treatment of sarcoidosis. The monoclonal antibody targets the inflammatory response known to occur in patients living with this rare disease. TNFα is a pro-inflammatory cytokine released by immune cells that may promote the formation of harmful granulomas and fibrosis throughout the body of people with the condition. To date, strong early data supports this lead candidate as a potential next-generation treatment for this chronic, multisystem inflammatory disorder.
More About XTMAB-16MHAI-25
MAI-25 is an investigational, first-in-class intravenous (IV) epoxide antibiotic with a broad spectrum of bactericidal Gram-negative and Gram-positive activity, including activity against most contemporary MDR strains that threaten hospitalized patients. Fosfomycin IV has an extensive history from markets outside the U.S., where it has been utilized for over 45 years in nine indications. CONTEPO™ utilizes a new dosing approach, to optimize the compound’s pharmacokinetics and pharmacodynamics.
Our Pipeline
Brands
| Drug Name | Therapeutic Area | Type | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Submission |
|---|---|---|---|---|---|---|---|---|
| XTMAB-16 | Sarcoidosis | Biologic | ||||||
| MHAI-25 | Anti-Infective | Small Molecule | ||||||
You might also be interested
The brands mentioned here are the trademarks of their respective owners.